Overactivation of PARP-1 and parthanatos has been implicated in the development of various neurodegenerative diseases, and therefore suppression of parthanatos is thought to be a potential therapeutic strategy for neurodegenerative diseases (1). This evidence concerns the gene PARP1 and neurodegenerative disease.